26 November 2013
Preference of 15% can get the company that packaged medicines in Russia ( these preferences will be valid until the end of 2014 - after such producers cease to be considered local , say two members of yesterday's meeting at Manturov), 30 % - manufacturers of finished dosage forms , 40 % - establish a complete production cycle , ie, including the production of substances.
In 2012, the Russian pharmaceutical market reached 773 billion rubles . , Of this amount, 236 billion rubles . had a segment of the public procurement , analysts estimate DSM Group. The share of imported drugs on the market - 76%. Approximately 450 foreign companies operating in Russia , production of finished forms localized about 50 companies , of which about 20 have their own production , 30 - contract , still only about 30 in the country packed medicines DSM Group says CEO Sergei Shuljak .
Now for all acts of domestic producers a 15% preference if the winner of the auction becomes a local manufacturer, it enters into a contract at the price established in the course of trading and foreign must give a 15% discount .
Order granting preferences produces Economic Development. Ministry of Economic Development Ministry of Industry sent in their proposals , said ministry spokesman . The representative of the Ministry of Economic Development has not responded to the request , "Vedomosti" .
The proposed measures will contribute to the development of domestic pharmaceutical production and encourage foreign producers to pass on the full cycle of production of medicines in Russia , explains Manturov . This may affect companies that are directly involved in the auction , said deputy director of Stada CIS Ivan Glushkov . Drug prices may fall by about 30 %, while the share of domestic drugs on the market to grow , says co-owner of the developer and manufacturer of medicines " Biocad " Dmitry Morozov .
Premium of 10% for the organization of a full production cycle is not entirely true , says CEO of pharmaceutical company "R -Pharm " Vasily Ignatiev. The world's largest manufacturer of substances - China , Russia industry will have to create from scratch , he explains. The cost of building a plant to produce substances Ignatiev valued at approximately $ 100 million
Author: Maria Dranishnikova, www.vedomosti.ru
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024
CRISPR technologies fuelling haematological innovations
17 April 2024
17 April 2024